NCT07178743|CompletedFDA Drug
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Food and Drug Administration
observational
6,097
1 country
1
Study Start
July 14, 2025
Actual (reported)Primary Completion
March 1, 2026
Actual (reported)Study Completion
March 1, 2026
Actual (reported)Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 14, 2025
Actual (reported)September 8, 2025
Actual (reported)September 17, 2025
Actual (reported)March 1, 2026
Actual (reported)March 1, 2026
Actual (reported)Time to all-cause mortality (overall survival)
Hazard ratio (95% CI)
Through the earliest of outcome, censoring, or end of data (April 2024)
Time to next treatment (TTNT)
Through the earliest of outcome, censoring, or end of data (April 2024)
Exposure group
Reference group
Initiation of palbociclib plus letrozole described in electronic health records is used as the exposure.
Initiation of letrozole described in electronic health records is used as the reference.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Initiation of palbociclib plus letrozole
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordPostmenopausal women with ER-positive, HER2-negative locally advanced or metastatic breast cancer who receive treatment without curative intent
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Shirley Wang, PhD, ScM
Brigham and Women's Hospital
Denys Shay, MD
Brigham and Women's Hospital
6,097 participants (actual enrollment reported by the registry).
First Submitted
September 8, 2025
First Posted
September 17, 2025
Study Start
July 14, 2025
Actual (reported)Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 1, 2026
Actual (reported)Study Completion
March 1, 2026
Actual (reported)Last Updated
May 12, 2026
Record last verified: 2025-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: